Celularity Inc.

Equities

CELU

US1511902041

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:30:00 2024-04-26 pm EDT			5-day change	1st Jan Change
3.02 ^USD	-1.63%		-0.33%	+22.07%

Mar. 26	Celularity Receives Healthcare Common Procedure Coding System Q Code Approval from the U.S. Centers for Medicare & Medicaid Services for Biovance 3L	CI
Mar. 20	Celularity Seeks FDA Orphan Drug Status for PDA-002 in Facioscapulohumeral Muscular Dystrophy	MT

Celularity Inc. Confirms Commercialization Agreement with BioCellgraft, Inc. for Manufacture and Distribution of Advanced Biomaterial Products for Use in Oral Healthcare

January 04, 2024 at 01:00 pm EST

Celularity Inc. confirmed that it has entered into an exclusive U.S. strategic commercialization agreement with BioCellgraft Inc. under which Celularity will manufacture advanced biomaterial products for BioCellgraft which BioCellgraft will distribute in the United States for use in multiple dental/oral healthcare applications.

Latest news about Celularity Inc.

Celularity Receives Healthcare Common Procedure Coding System Q Code Approval from the U.S. Centers for Medicare & Medicaid Services for Biovance 3L	Mar. 26	CI
Celularity Seeks FDA Orphan Drug Status for PDA-002 in Facioscapulohumeral Muscular Dystrophy	Mar. 20	MT
Celularity Inc. announced that it expects to receive $10 million in funding from Yorkville Advisors Global LP	Mar. 12	CI
Celularity to Execute Reverse Stock Split Next Week	Feb. 23	MT
Celularity Inc. Provides Sales Guidance for the First Quarter and Full Year 2024	Feb. 01	CI
Celularity Insider Bought Shares Worth $5,331,335, According to a Recent SEC Filing	Jan. 17	MT
Genting Berhad Engages in Discussions with Celularity Inc	Jan. 17	CI
Celularity Inc. announced that it has received $6 million in funding from Dragasac Limited	Jan. 15	CI
Celularity Inc. announced that it expects to receive $6 million in funding from Dragasac Limited	Jan. 11	CI
Celularity, BioCellgraft Strike Deal for Placental-Derived Biomaterial Products	Jan. 04	MT
Celularity Inc. Confirms Commercialization Agreement with BioCellgraft, Inc. for Manufacture and Distribution of Advanced Biomaterial Products for Use in Oral Healthcare	Jan. 04	CI
Celularity Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year 2023	Jan. 03	CI
North American Morning Briefing : Stock Futures Extend Losses as FOMC Minutes Awaited	Jan. 03	DJ
Celularity Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Jan. 03	CI
Celularity Inc. Announces Resignation of Robin L. Smith, MD, from Board of Directors	Dec. 29	CI
North American Morning Briefing : S&P 500 Futures Dip with Fresh Record in Sight	Dec. 20	DJ
North American Morning Briefing : Traders Await FOMC, Powell	Dec. 13	DJ
North American Morning Briefing : Stock Futures Rise With More Jobs Data on Tap	Dec. 06	DJ
Celularity Receives Non-Compliance Notice From Nasdaq	Nov. 24	MT
North American Morning Briefing : Stock Futures Muted; Nvidia Slips in Offhours Trading	Nov. 22	DJ
Lim Kok Thay Notifies Celularity Inc. of His Intention to Resign as a Member of the Board and All Committees	23-09-19	CI
Celularity Inc.(NasdaqCM:CELU) dropped from S&P Global BMI Index	23-09-18	CI
Celularity Inc. Appoints Geoffrey Shiu Fei Ling, M.D., Ph.D. to its Board of Directors	23-09-07	CI
Celularity to Support Research of Regeneron's Allogeneic Cell Therapy Candidates for Solid Tumors	23-08-29	MT
Celularity Inc Announces Multi-Year Research Collaboration Services Agreement with Regeneron Pharmaceuticals, Inc	23-08-29	CI

Chart Celularity Inc.

Duration

Period

More charts

Company Profile

Celularity Inc. is a clinical-stage biotechnology company. The Company is engaged in developing off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer and immune and infectious diseases. It operates through three business segments: Cell Therapy, Degenerative Disease, and BioBanking. Its therapy product candidates include T cells engineered with a chimeric antigen receptor (CAR), natural killer, cells, mesenchymal-like adherent stromal cells (MLASCs), and exosomes. These therapeutic candidates target indications across cancer, infectious and degenerative diseases. Its cell therapeutic programs include CYCART-19, CYCART-201, CYNK-001, CYNK-301, CYNK-302, APPL-001, and pEXO-001. CYCART-19 is a placental-derived CAR-T cell therapy, in development for the treatment of B-cell malignancies, initially targeting the cluster of differentiation 19. pExo-001 is developed for the treatment of osteoarthritis. APPL-001 is developed for the treatment of Crohnâs disease.

Sector

Biotechnology & Medical Research

Calendar

2024-05-08 - American Society of Gene & Cell Therapy Meeting

More about the company

	1st Jan change	Capi.
CELULARITY INC.	+22.07%	65.78M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.73B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs

Celularity Inc.

Equities

CELU

US1511902041

Biotechnology & Medical Research

Celularity Inc. Confirms Commercialization Agreement with BioCellgraft, Inc. for Manufacture and Distribution of Advanced Biomaterial Products for Use in Oral Healthcare

Latest news about Celularity Inc.

Chart Celularity Inc.

Company Profile

Income Statement Evolution

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs